Delving into the Latest Updates on Cancer vaccine(Therion Biologics Corp.) with Synapse

Background:
Combination immunotherapy techniques are being explored to improve responses and enhance benefits in people with cancer. Researchers want to see if this type of treatment can help people with advanced solid tumors.
Objective:
To find a safe dose of SX-682 in combined treatment with Bintrafusp alfa and BN-CV301 vaccines and to see if this treatment will cause tumors to shrink.
Eligibility:
Adults age 18 and older with metastatic cancer may be eligible for the first part of the trial. Adults age 18 and older with metastatic triple negative breast cancer or p16 negative head and neck squamous cell cancer, and who are not candidates for curative surgery may be eligible for the second part of the trial.
Design:
Participants will be screened under a separate protocol.
Participants may have tumor biopsies. They will have physical exams. Their symptoms and medicines will be reviewed. They will have blood tests. They will have electrocardiograms to evaluate their heart.
Participants will have imaging scans of the chest, abdomen, and pelvis. They may have a procedure where a small tube with a tiny video camera is put into the nose to look at the throat if they have head and neck cancers.
Participants will get bintrafusp alfa through an intravenous catheter. For this, a small tube is put into an arm vein. They will get BN-CV301 vaccines as injections in the arm or thigh. They will take SX-682 by mouth twice a day. They will take the study drugs up to 2 years. They will keep a medicine diary.
Participants will have study visits every 2 weeks. They will have 1 or 2 follow-up visits within 30 days after they stop treatment. Then they will be monitored by phone or email for 2 years.

Start Date24 Nov 2020

Sponsor / Collaborator

National Cancer Institute

NCT04491955 / Active, not recruitingPhase 2IIT

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Background:
Metastatic or refractory/recurrent small bowel and colorectal cancers cannot be cured and are often not helped by standard treatments. Researchers want to find better treatments by testing a combination of drugs.
Objective:
To learn if a new combination of immunotherapy drugs can shrink tumors in people with advanced small bowel and colorectal cancers.
Eligibility:
People ages 18 and older who have advanced metastatic or refractory/recurrent small bowel and/or colorectal cancer.
Design:
Participants will be screened on a separate protocol. They will have a physical exam and medical history. They will have imaging scans. They will have blood and urine tests. Their heart function will be measured. They may have a tumor biopsy.
Participants will repeat some of the screening tests during the study.
Participants will be put into study groups. Each group will get a combination of the following drugs: CV301 vaccine (modified vaccinia Ankara (MVA)-BN-CV301 and Fowlpox (FPV)-CV301), M7824 (MSB0011359C), and N-803 (Anktiva). Some will also get NHS-IL12 (M9241).
Participants will get the CV301 vaccines by injection under the skin. They will get M7824 by intravenous infusion every 2 weeks. They will get N-803 by injection under the skin every 2 or 4 weeks. They may get NHS-IL12 by injection under the skin every 4 weeks. They will take the study drugs for up to 1 year. They will visit the National Institutes of Health (NIH) every 2 weeks.
After treatment ends, participants will go to the clinic for a 28-day follow-up visit or have a telephone call. They will be contacted every 3 months for 1 year, and then every 6 months after that for the rest of their life.

Start Date22 Sep 2020

Sponsor / Collaborator

National Cancer Institute

NCT03628716 / CompletedPhase 2

A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

This is a Phase 2, single-arm, multi-institutional clinical trial designed to study the combination of CV301 with atezolizumab in the first-line treatment of UC not eligible for cisplatin-containing chemotherapy (Cohort 1) and in the second-line treatment of UC previously treated with standard first-line cisplatin-based chemotherapy (Cohort 2).

Start Date18 Sep 2018

Sponsor / Collaborator

Bavarian Nordic A/S

100 Clinical Results associated with Cancer vaccine(Therion Biologics Corp.)

Login to view more data

100 Translational Medicine associated with Cancer vaccine(Therion Biologics Corp.)

Login to view more data

100 Patents (Medical) associated with Cancer vaccine(Therion Biologics Corp.)

Login to view more data

28

Literatures (Medical) associated with Cancer vaccine(Therion Biologics Corp.)

01 Mar 2023·Cancer immunology, immunotherapy : CII

Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma

Article

Author: Kilbridge, Kerry L ; McGregor, Bradley Alexander ; Montgomery, Robert B ; Cheng, Heather H ; Maughan, Benjamin Louis ; Jain, Rohit ; Wei, Xiao X ; Perschy, Teresa ; Gafoor, Zarina ; Grewal, Jaspreet S ; Schweizer, Michael Thomas ; Hsieh, Andrew Caleb ; Lee, Richard J ; Sonpavde, Guru P ; Grivas, Petros ; Pico-Navarro, Cesar ; Yu, Evan Y

CV301 comprises recombinant poxviruses, Modified Vaccinia Ankara (MVA) and Fowlpox (FPV), encoding CEA, MUC-1, and co-stimulatory Molecules (TRICOM) ICAM-1, LFA-3, and B7-1. MVA-BN-CV301 is used for priming and FPV-CV301 is used for boosting. A Phase 2, single-arm trial was designed to evaluate CV301 plus atezolizumab as first-line treatment for cisplatin-ineligible advanced urothelial carcinoma (aUC) (Cohort 1) or progressing after platinum chemotherapy (Cohort 2). MVA-CV301 was given subcutaneously (SC) on Days 1 and 22 and FPV-CV301 SC from day 43 every 21 days for 4 doses, then tapered gradually over up to 2 years. Atezolizumab 1200 mg IV was given every 21 days. The primary endpoint was objective response rate (ORR). Overall, 43 evaluable patients received therapy: 19 in Cohort 1; 24 in Cohort 2; nine experienced ≥ Grade 3 therapy-related adverse events. In Cohort 1, one had partial response (PR) (ORR 5.3%, 90% CI 0.3, 22.6). In Cohort 2, 1 complete response and 1 PR were noted (ORR 8.3%, 90% CI 1.5, 24.0). The trial was halted for futility. Patients exhibiting benefit demonstrated T-cell response to CEA and MUC-1. The trial illustrates the challenges in the development of vaccines, which should be guided by robust preclinical data.

01 Feb 2023·International journal of cancer

Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer

Article

Author: Menius, Erika ; Schlom, Jeffrey ; Devarakonda, Siddhartha ; Rajan, Arun ; Gulley, James L. ; Korchin, Borys ; Donahue, Renee N. ; Birhiray, Ruemu ; Gray, Jhanelle E.

Abstract:

CV301, a poxviral‐based vaccine, has been evaluated in a phase 1 clinical trial (NCT02840994) and shown to be safe and immunologically active (phase 1a). Preclinical data support a combination of CV301 with programmed death‐1 inhibitors, which has been evaluated in the phase 1b part of this trial and is reported here. Patients with advanced nonsquamous non‐small cell lung cancer (NSCLC) without actionable genomic alterations received two priming doses of modified vaccinia Ankara‐BN‐CV301 (MVA) 4 weeks apart, followed by boosting doses of fowlpox‐CV301 (FPV) at increasing time intervals for a maximum of 17 doses in combination with nivolumab for cohort 1 (C1) and 15 doses in combination with pembrolizumab for cohort 2 (C2). The primary objective was evaluation of safety and tolerability. Between October 2017 and September 14, 2018, patients were enrolled (C1: 4; median age: 64 years). Mean treatment duration was 332 days in C1 and 289 days in C2. CTCAE ≥grade 3 adverse events (AEs) were observed in four (100%) patients in C1 and three (37.5%) patients in C2. There was one death on trial. Immune‐related AEs (irAEs) fulfilling criteria for a dose‐limiting toxicity included 1 case of pneumonitis. Among 11 evaluable patients, 1 (9%) had a complete response, 1 (9%) had a partial response and 9 (82%) had stable disease. We conclude that CV301 administered with PD‐1 inhibitors is safe and clinically active in patients with advanced NSCLC. The frequency or severity of AEs is not increased, including irAEs for each component of the combination.

01 Jun 2022·Public health nutritionQ3 · MEDICINE

Perceptions of a food benefit programme that includes financial incentives for the purchase of fruits and vegetables and restrictions on the purchase of foods high in added sugar

Q3 · MEDICINE

Article

Author: Harnack, Lisa J ; Lasswell, Tessa ; Oakes, J Michael ; Fagbenro, Fatima A ; Rydell, Sarah A ; Elbel, Brian

Abstract:

Objective::

To report perspectives of participants in a food benefit programme that includes foods high in added sugar (FAS) restrictions and FAS restrictions paired with fruits and vegetables (F/V) incentives.

Design::

Randomised experimental trial in which participant perspectives were an exploratory study outcome.

Setting::

Participants were randomised into one of three Supplemental Nutrition Assistance Program (SNAP)-like food benefit programme groups: (1) restriction: not allowed to buy FAS with benefits; (2) restriction paired with incentive: not allowed to buy FAS with benefits and 30 % financial incentive on eligible F/V purchased using benefits; or (3) control: same food purchasing rules as SNAP. Participants were asked questions to assess programme satisfaction.

Participants::

Adults in the Minneapolis-St. Paul, MN metropolitan area, eligible for but not currently participating in SNAP who completed baseline and follow-up study measures (n 254).

Results::

Among remaining households in each group, most found the programme helpful in buying nutritious foods (88·2 %–95·7 %) and were satisfied with the programme (89·1 %–93·0 %). Sensitivity analysis results indicate that reported helpfulness and satisfaction with the programme may in some instances be lower among the restriction and the restrictions paired with incentive groups in comparison to the control group.

Conclusions::

A food benefit programme that includes restriction on purchase of FAS or restriction paired with a financial incentive for F/V purchases may be acceptable to most SNAP-eligible households with children.

100 Deals associated with Cancer vaccine(Therion Biologics Corp.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bladder Cancer	Phase 2	US	Bavarian Nordic A/S	18 Sep 2018
Adenocarcinoma of large intestine	Phase 2	US	Bavarian Nordic A/S	08 Aug 2018
Adenocarcinoma of large intestine	Phase 2	US	MedImmune LLC	08 Aug 2018
Pancreatic adenocarcinoma metastatic	Phase 2	US	Bavarian Nordic A/S	08 Aug 2018
Pancreatic adenocarcinoma metastatic	Phase 2	US	MedImmune LLC	08 Aug 2018
Secondary malignant neoplasm of pancreas	Phase 2	US	MedImmune LLC	08 Aug 2018
Secondary malignant neoplasm of pancreas	Phase 2	US	Bavarian Nordic A/S	08 Aug 2018
Metastatic colon cancer	Phase 2	US	Bavarian Nordic A/S	26 Jun 2018
Metastatic Colorectal Carcinoma	Phase 2	US	Bavarian Nordic A/S	26 Jun 2018
Prostatic Cancer	Phase 2	US	National Cancer Institute	10 Apr 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04491955 (CTgov)	Phase 2	Colorectal Cancer \| Small intestine carcinoma	32	NHS-IL12 (M9241) (Cohort 1, Arm 1 Triple Therapy Without NHS-IL12 (M9241))	kyhzofcqlb(dkdsfcchqc) = wdwllyxkxx bdmcwhjnon (sdwpuwbkob, jtqjpgdgas - pnktkeknka) View more	-	14 Nov 2023
				Fowlpox (FPV)-CV301+N-803+modified vaccinia Ankara (MVA)-BN-CV301+M7824+NHS-IL12 (Cohort 2, Arm 2a Dose Level (DL) 1, Quad Therapy Dose Escalation)	nxxcjiizqd(eeprhdfoaa) = fvfsexlbcs wywwjdyljn (jfbdpgiluz, durtbzsxcs - yrnhpjbihs) View more
NCT03547999 (HCRN GI16-288, ASCO_GI2023) Manual	Phase 2	Metastatic Colorectal Carcinoma First line MSS	17	mFOLFOX + nivolumab	norfdpchut(dbzvhhgcoi) = mfugoeshxr jercditcwg (gaaxexzytb ) View more	Positive	24 Jan 2023
				mFOLFOX + nivolumab + CV301	norfdpchut(dbzvhhgcoi) = xdktfrfltl jercditcwg (gaaxexzytb ) View more
NCT04491955 (ASCO_GI2023) Manual	Phase 2	Advanced Colorectal Adenocarcinoma \| Small intestine carcinoma Second line	30	overall	iwuweztmyk(sqyjxgmnhl) = tnzazpjjhl vgvlztqmkw (ngqbqnfwck )	Positive	24 Jan 2023
				CV301+N-803+bintrafusp alfa (triple therapy)	zpnwxrcwid(fgspaslove) = yixzddkvdw vwhwtqtmvl (itocaeilte, 33.7 - 86.0) View more
NCT03376659 (CTgov)	Phase 1/2	Adenocarcinoma of large intestine \| Pancreatic adenocarcinoma metastatic \| Secondary malignant neoplasm of pancreas ... View more	8	CV301+Bevacizumab+Durvalumab+Capecitabine	suwooisdtt(pmpnhrltas) = kvqgyzybpl jytzqjvapz (cuhqjihlfo, olpjipjxau - yadcgjyjqj) View more	-	10 Jan 2023
NCT03628716 (CTgov)	Phase 2	Bladder Cancer	43	Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 1))	srjghhdvka(xpwxacmeki) = iwglmyywgq ddalcyamkg (jrewztmkno, qyzslacxyb - uwksnmonil) View more	-	27 Apr 2022
				Atezolizumab+CV301 (CV301 + Atezolizumab (Cohort 2))	srjghhdvka(xpwxacmeki) = qhhmqbdiop ddalcyamkg (jrewztmkno, hwhvkhjfkf - yczxlkypts) View more
NCT03628716 (ASCO_GU2022)	Phase 2	Advanced Urothelial Carcinoma	43	CV301 vaccine plus atezolizumab	xhcgtxduma(tbxugfcipa) = eyyekpzudb rkyamhgskq (crbtlttpdo, 0.3, 22.6) View more	Negative	16 Feb 2022
NCT02015104 (CTgov)	Phase 2	Carcinoma of urinary bladder, invasive \| Non-Muscle Invasive Bladder Neoplasms	32	BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG))+PANVAC (Bacillus Calmette-Guerin (BCG) + PANVAC)	wkjxjroqdn(xzcswlpyga) = ubjyajpuhp amuezevtfi (wkvwyszghs, iptrwvobif - hpefwnvyfp) View more	-	22 Jan 2020
				BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)) (Bacillus Calmette-Guerin (BCG) Alone)	wkjxjroqdn(xzcswlpyga) = tzfacuxvxe amuezevtfi (wkvwyszghs, qigbtlzlxt - rrpwbapbko) View more
NCT02840994 (ESMO2019) Manual	Phase 1	Squamous non-small cell lung cancer	12	nivolumab+CV301 (patients pre-treated with platinum-containing chemotherapy)	wadeigipvh(xzdvdxsyhm) = 3/4 C1 and 3/8 C2 pts with 1 fatal tabpyajarl (kzjugkclkq ) View more	Positive	30 Sep 2019
				pembrolizumab+CV301 (patients receiving frontline treatment with pembrolizumab after a minimum of 11 weeks of SD per RECIST)
NCT00179309 (Pubmed \| JAMA Oncol)	Phase 2	Metastatic breast cancer	48	Docetaxel with PANVAC	zjvvjkdovf(jfsnngazho) = ovmavrnibc scvnkprutn (btruewlmla )	Positive	01 Nov 2015
				Docetaxel alone	zjvvjkdovf(jfsnngazho) = tuweatbzed scvnkprutn (btruewlmla )
NCT00103142 (CTgov)	Phase 2	Secondary malignant neoplasm of lung \| Neoplasm Metastasis \| Colorectal Cancer	74	therapeutic autologous dendritic cells+falimarev (PANVAC-V + PANVAC-F + DC)	xtyrymyhcn(kkditptjpu) = fsuiupcboe votvfjkqam (wiihwpansa, ezwndelquo - vepvyymwoc) View more	-	07 Apr 2014
				falimarev+sargramostim (PANVAC-V + PANVAC-F + GM-CSF)	xtyrymyhcn(kkditptjpu) = wgmecuyswc votvfjkqam (wiihwpansa, gnhyajvgma - qnibznmkcj) View more